Op-Sci is developing a first in market AI technology to help 150M patients worldwide from going blind in a $7B market. The IOPerfect visor bridges the competition’s unmet need for user-friendly, accurate and affordable eye pressure tracking, a key biomarker for glaucoma management. Our team has over seventy years of combined experience backed by the world’s top glaucoma surgeons. We were already awarded $1.4M USD to reach proof of concept and are now seeking additional financing to get us to market readiness in 2023.
BrainWatch Tech is developing a real-time, continuous, automatic pupil reflex monitoring system for assessing the neurological status of unconscious patients in cases of traumatic brain injury, stroke, and brain surgery. The technology behind BrainWatch is an automatic monitoring system of the pupillary light reflex through closed eyes, using an optical system for image acquisition and AI for image and data analysis. BrainWatch's solution continuously monitors pupillary activity in unconscious patients through closed eyes, immediately alerting surgeons and staff to changes in the patient's condition. The system also enables pupil monitoring in real time during complex brain surgery. The product will look like a pair of virtual reality goggles, equipped with a camera lens and a light that will continuously monitor, measure, and record pupil size and reflex through the closed eyelids of patients with severe brain injury. The continuous monitoring will create a record of the patient's condition and response to treatment over time. BrainWatch Tech was established in the eHealth Ventures incubator, which fosters early-stage digital health start-ups.
Olive Diagnostics
Seed Round in 2019
It's About me (IAM) has developed a passive sensor mounted to the rim of the toilet that performs urinalysis every time the end-user urinates. The information is uploaded to a robust data science platform to track existing and progressing conditions. Real-time, actionable notifications will be sent to the end user for proactive medical or nutritional care. Ongoing biomarker tracking for hydration, Alcohol, Pregnancy, Ovulation, Keytones, etc. is used to develop a comprehensive personal user profile. The technology will also be used for pharma and CRO companies to track the usage of drugs. While drug compliance issues plague health care systems around the world, I AM's technology will provide a reliable and continuous solution for tracking when and how people take their medicine or clinical trial drug. Nonindustrial nations will now have home access to urine lab services.
Allerguard Ltd. is a company based in Tel Aviv, Israel, specializing in the development of personal allergy detection systems. Founded in 2017, Allerguard's innovative technology allows users to scan their food for allergens using a device equipped with allergen sensors that analyze food compounds. Unlike other portable detection devices that require food sampling, Allerguard's system uniquely detects allergen particles by analyzing the vapors of the meal, providing alerts to users about any potential allergens present. The device is designed to identify allergens down to the maximum levels considered safe for consumption by the International Food Industry, ensuring greater safety for individuals with food allergies.
Op-Sci is developing a first in market AI technology to help 150M patients worldwide from going blind in a $7B market. The IOPerfect visor bridges the competition’s unmet need for user-friendly, accurate and affordable eye pressure tracking, a key biomarker for glaucoma management. Our team has over seventy years of combined experience backed by the world’s top glaucoma surgeons. We were already awarded $1.4M USD to reach proof of concept and are now seeking additional financing to get us to market readiness in 2023.
EfA’s product: RevDx (Revolutionary Diagnostics), is a mobile, portable, handheld, ,end-point solution that includes an innovative method to perform an automatic computerized microscopy like inspection, including a whole blood sampling and an automatic diagnosis of blood count and other applications to be followed. The product is an easy-to-operate, based on a finger prick and without the need for laboratory conditions and specific preparations. For example, you will be able to make a real-time informed decision about the unnecessary use of antibiotic treatment and the necessity of continued clarification. This product will be an essential device for every point-of-need around the world.
TrainPain is an early stage digital therapeutics company developing an innovative digital treatment for chronic neuropathic pain. Our low cost home based platform assesses and treats pain related neuroplasticity using a proprietary tactile stimulation device and sensory perception tasks embedded into captivating mobile video games.
SensoGenic strive to enhance our users’ every day experiences with our innovative and insightful technology. Founded in 2016, their incredible team of engineers, programmers, designers, and marketing experts have worked tirelessly to bring SensoGenic to the forefront of the Startup world.
They strive to provide excellence to all of our users; SensoGenic researches their habits, their motives, and what they really want in a product. They then internalize and synthesize all of this information to improve upon our own business and product. They have, and will continue to work relentlessly to become the technological standard, providing big picture insights which industry leaders not only approve of, but depend on as well.
Allerguard Ltd. is a company based in Tel Aviv, Israel, specializing in the development of personal allergy detection systems. Founded in 2017, Allerguard's innovative technology allows users to scan their food for allergens using a device equipped with allergen sensors that analyze food compounds. Unlike other portable detection devices that require food sampling, Allerguard's system uniquely detects allergen particles by analyzing the vapors of the meal, providing alerts to users about any potential allergens present. The device is designed to identify allergens down to the maximum levels considered safe for consumption by the International Food Industry, ensuring greater safety for individuals with food allergies.
DermaDetect was co-founded a year ago by four experienced entrepreneurs and is clinically led by Prof. Arieh Ingber, former head of department of dermatology in Hadassa Medical Center in Israel, a world-renowned dermatologist. We've developed a diagnostics & treatment tool/app (Apple, Android, Web), which enables healthcare professionals and patients to self-triage & manage skin disorders. The underlying technology is based on the combination of two approaches: dermatological rule base inference & image analysis using machine learning. We’re in a progress of a pilot-study to validate the effectiveness of our technology within the Israeli Health system, which is world’s best sandbox for such a study. Funded by two angel investors, eHealth Ventures [and their partners: Maccabi Healthcare Services in Israel (second biggest HMO in Israel), the Cleveland Clinic (the second largest healthcare provider in the US), Amgen], and supported by the Israel Innovation Authority.